Informations générales (source: ClinicalTrials.gov)
European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
Interventional
Phase 3
University of Giessen (Voir sur ClinicalTrials)
octobre 2015
septembre 2026
13 septembre 2025
The EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial
with the aims to reduce the indication for radiotherapy in newly diagnosed patients with
classical Hodgkin lymphoma without compromising cure rates and to investigate a
chemotherapy intensification randomisation in intermediate and advanced classical Hodgkin
lymphoma to compensate for reduction in radiotherapy.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 10/04/2025 13:12:18 | Contact (sur clinicalTrials) | |||
| CLCC INSTITUT GUSTAVE ROUSSY | Charlotte RIGAUD | 07/05/2024 12:52:01 | Contacter | ||
Critères
Tous
Inclusion Criteria:
- histologically confirmed primary diagnosis of classical Hodgkin's lymphoma
- patients under 18 years of age on the date of written informed consent. In
specialized Teenage and Young Adult (TYA) units in France, Italy and UK patients up
to under 25 years of age can also be enrolled. Lower age limits will be country
specific according to national laws or formal insurance requirements that may
preclude very young patients.
- written informed consent of the patient and/or the patient's parents or guardian
according to national laws
- negative pregnancy test within 2 weeks prior to starting treatment for female
patients with childbearing potential
- histologically confirmed primary diagnosis of classical Hodgkin's lymphoma
- patients under 18 years of age on the date of written informed consent. In
specialized Teenage and Young Adult (TYA) units in France, Italy and UK patients up
to under 25 years of age can also be enrolled. Lower age limits will be country
specific according to national laws or formal insurance requirements that may
preclude very young patients.
- written informed consent of the patient and/or the patient's parents or guardian
according to national laws
- negative pregnancy test within 2 weeks prior to starting treatment for female
patients with childbearing potential
- prior chemotherapy or radiotherapy for other malignancies
- pre-treatment of Hodgkin's lymphoma (except for 7-10 days steroid pre-phase of a
large mediastinal tumour)
- diagnosis of lymphocyte-predominant Hodgkin's lymphoma
- other (simultaneous) malignancies
- contraindication or known hypersensitivity to study drugs
- severe concomitant diseases (e.g. immune deficiency syndrome)
- known HIV-positivity
- residence outside the participating countries where long term follow-up cannot be
guaranteed
- pregnancy and/or lactation
- patients who are sexually active and are unwilling to use adequate contraception
during therapy and for one month after last trial treatment
- current or recent (within 30 days prior to date of written informed consent)
treatment with another investigational drug or participation in another
interventional clinical trial